Published in Trends Mol Med on November 04, 2016
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet (2012) 15.21
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Stability and flexibility of epigenetic gene regulation in mammalian development. Nature (2007) 14.57
Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med (1998) 14.39
Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol (2003) 11.48
T cell exhaustion. Nat Immunol (2011) 11.08
Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity (2007) 10.83
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol (2008) 10.26
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature (1993) 9.81
Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med (2000) 9.36
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity (1999) 6.10
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med (1999) 6.09
Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med (1998) 5.78
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 5.60
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol (2015) 5.49
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet (2014) 5.42
Naive and memory CD4+ T cell survival controlled by clonal abundance. Science (2006) 4.67
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A (2010) 4.56
Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol (2012) 4.44
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science (2012) 3.39
Adoptive cell transfer as personalized immunotherapy for human cancer. Science (2015) 3.19
Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A (2008) 3.14
A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. Immunity (2009) 2.64
Ablation of CD8 and CD4 T cell responses by high viral loads. J Immunol (2003) 2.63
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell (2015) 2.52
Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity (2011) 2.49
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA (2016) 2.41
A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. J Virol (2000) 2.26
Immune microenvironments in solid tumors: new targets for therapy. Genes Dev (2011) 2.08
Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother (2004) 1.99
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature (2015) 1.98
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med (2015) 1.87
Adoptive cellular therapy: a race to the finish line. Sci Transl Med (2015) 1.82
Dynamic regulation of transcriptional states by chromatin and transcription factors. Nat Rev Genet (2013) 1.75
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Cancer Cell (2015) 1.74
How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology (2012) 1.66
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med (2014) 1.59
Rapid demethylation of the IFN-gamma gene occurs in memory but not naive CD8 T cells. J Immunol (2006) 1.58
T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol (2013) 1.57
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood (2014) 1.52
Histone acetylation facilitates rapid and robust memory CD8 T cell response through differential expression of effector molecules (eomesodermin and its targets: perforin and granzyme B). J Immunol (2008) 1.44
Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. J Virol (2012) 1.39
The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res (2012) 1.37
Global DNA methylation remodeling accompanies CD8 T cell effector function. J Immunol (2013) 1.27
Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion. Immunity (2016) 1.27
Defining CD8(+) T cells that provide the proliferative burst after PD-1 therapy. Nature (2016) 1.24
Differentiation-dependent functional and epigenetic landscapes for cytokine genes in virus-specific CD8+ T cells. Proc Natl Acad Sci U S A (2011) 1.18
Distinct epigenetic signatures delineate transcriptional programs during virus-specific CD8(+) T cell differentiation. Immunity (2014) 1.14
Cutting edge: Prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells. J Immunol (2013) 1.14
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol (2016) 1.12
Cutting edge: persistently open chromatin at effector gene loci in resting memory CD8+ T cells independent of transcriptional status. J Immunol (2011) 1.09
Follicular CXCR5-expressing CD8(+) T cells curtail chronic viral infection. Nature (2016) 1.04
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 0.99
Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. J Clin Invest (2015) 0.96
Regulation of DNA methylation dictates Cd4 expression during the development of helper and cytotoxic T cell lineages. Nat Immunol (2015) 0.95
Engineering CAR-T cells: Design concepts. Trends Immunol (2015) 0.93
Mechanisms of epigenetic memory. Trends Genet (2014) 0.91
T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections. Immunity (2016) 0.91
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. Immunity (2016) 0.89
Combining Epigenetic and Immunotherapy to Combat Cancer. Cancer Res (2016) 0.88
Epigenetic manipulation restores functions of defective CD8⁺ T cells from chronic viral infection. Mol Ther (2014) 0.85
Lineage relationship of CD8(+) T cell subsets is revealed by progressive changes in the epigenetic landscape. Cell Mol Immunol (2015) 0.85
Learning from PD-1 Resistance: New Combination Strategies. Trends Mol Med (2016) 0.84
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell (2016) 0.80
Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model. Cancer Immunol Res (2015) 0.80
Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion. J Virol (2016) 0.76
Tumor-Specific Effector CD8+ T Cells That Can Establish Immunological Memory in Humans after Adoptive Transfer Are Marked by Expression of IL7 Receptor and c-myc. Cancer Res (2015) 0.76
Generating long-lived CD8(+) T-cell memory: Insights from epigenetic programs. Eur J Immunol (2016) 0.75
New advances in CMV and immunosenescence. Exp Gerontol (2014) 0.98